{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-035886","form_type":"8-K","ticker":"PRME","cik":"0001894562","company_name":"Prime Medicine, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.134113+00:00","generated_at":"2026-05-31T11:19:07.532895+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Prime Medicine Q2 net loss $55.3M; FDA clears PM359 for CGD Phase 1/2 trial","bullets":["FDA cleared IND for PM359 (Prime Editor for chronic granulomatous disease); Phase 1/2 trial initiating, initial data expected 2025.","Net loss $55.3M vs $42.4M YoY; R&D expenses $43.1M up from $34.6M; G&A $12.6M vs $10.7M.","Cash, equivalents, investments & restricted cash $176.4M as of June 30, 2024 (up from $135.2M Dec 31, 2023).","Promoted Mohammed Asmal, M.D., Ph.D. to Chief Medical Officer, effective immediately; he was SVP Head of Clinical since 2022.","Pipeline milestones: liver IND/CTA expected H2 2025–H1 2026; ocular candidate nomination for RHO-RP in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-035886","json":"https://secwatch.observer/filing/0001628280-24-035886.json","markdown":"https://secwatch.observer/filing/0001628280-24-035886.md","text":"https://secwatch.observer/filing/0001628280-24-035886.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1894562/000162828024035886/0001628280-24-035886-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1894562/000162828024035886/prme-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:19:07.532895+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}